Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-Human, Randomized, Dose-Escalation, Double-Blind, Placebo-Controlled Study to Assess Safety, Tolerability and Pharmacokinetics of APX001 Administered by Intravenous Infusion to Healthy Subjects

NCT02956499 is registered in ClinicalTrials.gov with Basilea Pharmaceutica as lead sponsor.

NCT NCT02956499
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02956499 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-Human, Randomized, Dose-Escalation, Double-Blind, Placebo-Controlled Study to Assess Safety, Tolerability and Pharmacokinetics of APX001 Administered by Intravenous Infusion to Healthy Subjects
Lead sponsor
Basilea Pharmaceutica
Phase
Phase 1
Overall status
Completed
Start date
May 24, 2016
Completion date
July 3, 2017
Enrollment
200 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

fungal infection